Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates

NeuroImmunoModulation

Volumn 3, Issue 6, 1996, Pages 325-332

  Maestroni, Georges J M ^a   Conti, Ario ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Immunopharmacology; Melatonin; Melatonin receptors; Secondary immunodeficiency; T helper cells; Viral diseases

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DYNORPHIN B; ETOPOSIDE; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; MELATONIN; MELATONIN RECEPTOR; NALTREXONE;

ANIMAL CELL; ANIMAL MODEL; ARTHRITIS; BACTERIAL INFECTION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PINEAL BODY; PINEAL GLAND FUNCTION; PRIORITY JOURNAL; RAT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LEUKEMIA; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CIRCADIAN RHYTHM; HEMATOPOIETIC SYSTEM; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY; MELATONIN; MICE; PINEAL GLAND;

EID: 12644273783     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000097292     Document Type: Article

References (66)

1. Yu HS, Reiler RJ: Melatonin. Biosynthesis. Physiological Effects, and Clinical Applications. Boca Raton. CRC Press, 1993
2. Deguchi T, Axelrod J: Control of circadian change of serotonin-N-acetyltransferase in the pineal organ by P-adrencrgic receptor. Proc Nat1 AcadSci USA 1973:70:2411-2414.
3. Yu HS, Tsin ATC, Reiter RJ: Melatonin: History'. biosynthesis, and assay methodology: in Yu HS. Reiter RJ (cds): Melatonin. Biosynthesis. Physiological Effects, and Clinical Applications. Boca Raton. CRC Press, 1993. pp 1-17.
4. Pang SF, Lee PPN, Chan YS, Reiter RJ: Melatonin secretion and its rhythms in biological fluids: in Yu HS. Reiter RJ (eds): Melatonin. Biosynthesis. Physiological Effects, and Clinical Applications. Boca Raton. CRC Press. 1993, pp 129-155.
5. Csaba G, Bodockv M, Fischer J, Acs T: The effect of pinealectomy and thymectomy on the immune capacity of the rat. Experientia 1965: 22:168-175.
6. Bindoni M, Cambria A: Effects of pincalccto-my on the in vivo and in vitro biosynthesis of nucleic acids on the mitotic rate in some organs of the rat. Arch Sci Biol 1968:52:271-283.
7. Rella W, Lapin V: Immunocompctcnce of pi-ncalectomizcd and simultaneously pincalccto-mized and thymectomized rats. Oncology 1978:33:3-6.
8. Jankovic BD, Isakovic S, Petrovic S: Effect of pinealectomy on immune reactions in the rat. Immunology 1970;8:1-6.
9. Vaughan MK, Reiter RJ: Transient hypertrophy of the ventral prostate and coagulating glands and accelerated thymic involution following pinealectomy in the mouse. Tex Rep Biol Med 1971:29:579-586.
10. Barath P, Csaba G: Histological changes in the lung, thymus and adrenal one and half year after pinealectomy. Acta Biol Acad Sci Hung 1974:25:123-125.
11. Csaba G, Barath P: Morphological changes of thymus and the thyroid gland after postnatal extirpation of pineal body. Endocrinol Exp 1975:9:59-67.
12. Maestroni GJM, Pierpaoli W: Pharmacological control of the hormonally modulated immune response; in Adcr R (cd): Psychoncuroimmu-nology. New York, Academic Press. 1981. pp 405-425.
13. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonize the immunosuppressive effect of corticosterone. J Neu-roimmunol 1986;13:19-30.
14. Conti A, Haran-Ghera N, Maestroni GJM: Role of pineal melatonin and melatonin-in-duced-immuno-opioids in murine leukemo-genesis. Med Oncol Tumor Pharmacothcr 1992:9:87-92.
15. Becker J, Veit G, Handgretinger R, Altanasio G, Bruchctt G. Trenner I, Niethammcr D. Gupta D: Circadian variations in the immunomodulatory role of the pineal gland. Neuroen-docrinol Lett 1988:10:65-80.
16. Champncy TH, McMurray DN: Spleen morphology and lymphoproiiferative activity in short photopcriod exposed hamsters: in Fras-chini F. Reiter RJ (cds): Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. London. Plenum. 1991. pp 219-225.
17. Del Gobbo V, Libri V, Villani N, Calio R, Nsti-co G: Pinealectomy inhibits intcrlcukin-2 production and natural killer activity in mice. Int J Immunopharmacol 1989:11:567-577.
18. Palermo MS, Vermeulen M, Giordano M: Modulation of antibody-dependent cellular cytotoxicity by pineal gland: in Maestroni GJM. Conti A. Reiter RJ (eds): Advances in Pineal Research. London. Libbey. 1994. vol 7. pp 143-147.
19. Haidar C, Haussler D, Gupta D: Response of CFU-GM (colony forming units for granulocytes and macrophages) from intact and pincal-cctomizcd rat bone marrow to macrophage colony stimulating factor (rGM-CSF) and human recombinant erythropoietin (rEPO). Prog Brain Res 1992:91:323-325.
20. Blask DE: Melatonin in oncology; in Yu HS. Reiter RJ (cds): Melatonin. Biosynthesis. Physiological Effects, and Clinical Applications. Boca Raton. CRC Press. 1993. pp 447-477.
21. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity: 11. Melatonin enhances the antibody response via an opiater-gic mechanism. Clin Exp Immunol. 1987:68: 384-391.
22. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. 111. Melatonin antagonizes the immunosuppressive effect of acute stress via an opiatergic mechanism. Immunology 1988:63:465-469.
23. Maestroni GJM, Conti A: Bcta-cndorphin and dynorphin mimic the circadian immunoen-hancingand anti-stress effects of melatonin. Int J Immunopharmacol 1989:11:333-340.
24. Maestroni GJM, Conti A: The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancingand anti-stress properties. J Neuroimmunol 1990:28:167-176.
25. Maestroni GJM, Conti A: Melatonin in relation to the immune system: in Yu HS, Reiter RJ (cds): Melatonin. Biosynthesis. Physiological Effects and Clinical Applications. Boca Raton. CRC Press. 1993. pp 290-306.
26. Maestroni GJM: The immunoncurocndocrinc role of melatonin. J Pineal Res 1993;14:1-10.
27. Maestroni GJM, Conti A, Reiter RJ (eds): Advances in Pineal Research. London. Hibbcy, 1994, vol 7.
28. Giordano M, Palermo MS: Melaionin-induccd enhancement of antibody-dependent cellular cytotoxicity. J Pineal Res 1991; 10:117-121.
29. Caroleo MC, Frasca D, Nistico G, Doria G: Melatonin as immunomodulator in immuno-dcftcient mice. Immunopharmacology 1992: 23:81-89.
30. Lissoni P, Bami S, Ardizzoia A. Brivio F. Tan-cini G. Conti A. Maestroni GJM: Immunological effects of a single evening subcutaneous injection of low-dosc intcrlcukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J Biol Regul Horn-cost Agents 1992;6:132-136.
31. Pioli C, Caroleo MC, Nistico G, Doria G: Melatonin increases antigen presentation and amplifies specific and nonspecific signals for T-ecll proliferation. Int J Immunopharmacol 1993:15:463-469.
32. Morrey MK, McLachlan JA, Scrkin CD, Ba-kouchc O: Activation of human monocytes by the pineal neurohormone melatonin. J Immunol 1994:153:2671-2680.
33. Ben-Nathan D, Maestroni GJM, Conti A: Protective effect of melatonin in mice infected with encephalitis viruses. Arch Virol 1995:140: 223-230.
34. Ben-Nathan D, Maestroni GJM, Conti A: Protective effect of melatonin in viral and bacterial infections: in Maestroni GJM. Conti A. Reiter RJ (eds): Frontiers in Hormone Research. Proc 2nd Locarno Meeting on Neurocndocrinoim-munology. Therapeutic Potential of the Pineal Hormone Melatonin. Locarno. Switzerland. Basel. Karger, in press.
35. Maestroni GJM: Melatonin as therapeutic agent in experimental endotoxic shock. J Pineal Res 1996:20:84-89.
36. Wichmann M, Zellweger R, DeMaso A, Ayala A, Chaudry I: Melatonin administration attenuates depressed immune functions trauma-hemorrhage. J Surg Res 1996:63:256-262.
37. Angeli A. Gatti G, Sanori ML, Del Ponte D, Cerignola R: Effect of exogenous melatonin on human natural killer (NK) cell activity. An approach to the immunomodulatory role of the pineal gland; in Gupta D. Altanasio A. Reiter RJ (eds): The Pineal Gland and Cancer. Tubingen. Miillcr & Bass. 1988, pp 145-157.
38. Lewinsky A, Zelazowskv P, Sewerynek E, Zer-ek-Melen G, Szudlinsky M: Melatonin-induced immunosuppression of human lymphocyte natural killer activity in vitro. J Pineal Res 1989:7:153-164.
39. Maestroni GJM, Conti A: Anti-stress role of the melatonin-immuno-opioid network. Evidence for a physiological mechanism involving T cell-derived, immunorcactive p-endorphin and met. enkephalin binding to thymic opioid receptors. Int J Ncurosci 1991:61:289-298.
40. Maestroni GJM, Covacci V, Conti A: Hematopoietic rescue via T-ccll-dcpendent. endogenous GM-CSF by the pineal ncurohormonc melatonin in tumor bearing mice. Cancer Res 1994;54:2429-2432.
41. Maestroni GJM, Conti A, Lissoni P: Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 1994;54:4740-4743.
42. Hansson I, Holmdahl R, Mattsson R: The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Ncuroimmunol 1992;39:23-31.
43. Colombo LL, Chen GJ, Lopez MC, Watson RR: Melatonin induced increase in gamma-interfcron production by murine splcnocytcs. Immunol Lett 1992;33:123-126.
44. Hofbauer LC, Hcufclder AE: Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. Eur J Endocrinol 1996; 134:424-425.
45. Guerrero JM, Garcia-Maurino S, Gil-Haba M, Rafii-El-Idrissi M, Pozo D. Garcia-Perganeda A. Calvo JR: Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors: in Maestroni GJM. Conti A. Reiter RJ (eds): Frontiers in Hormone Research. Proc 2nd Locarno Meeting on Neu-roendocrinoimmunology. Therapeutic Potential of the Pineal Hormone Melatonin Locarno, Switzerland. Basel. Kargcr. in press.
46. Maestroni G, Hertens E, Galli P, Conti A, Pedrinis E: Melatonin-induced T-helper cell hematopoietic cytokines resembling both inter-leukin-4 and dynorphin. J Pineal Res 1996; 131-139.
47. Ways E, Kutoh E, Gupta D: Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat. Eur J Endocrinol 1995;133:754-760.
48. Young MRI, Young ME, Kim K: Regulation of tumor-induced myelopoicsis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2. Cancer Res 1988;48:6826-6831.
49. Maestroni GJM: Kappa-opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines. Proc 3rd Int Congress Int Soc Neuroimmuno-modulation. Bethesda, New York Acad Sci, 1996. in press.
50. Rcppcrt SM, Weaver DR: Melatonin madness. Cell 1995;83:1059-1062.
51. Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF: Evidence for a direct action of melatonin on the immune system. Biol Signals 1994;3: 107-117.
52. Maestroni GJM: T helper 2 lymphocytes as a peripheral target of melatonin. J. Pineal Res 1995;18:84-89.
53. Konakchieva R, Kyurkchicv S, Kehayov I, Taushanova P, Kanchev L: Selective effect of methoxyindoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J Neuroimmunol 1995;63: 125-132.
54. Carlberg C, Wicscnberg I: The orphan receptor family RZR/ROR. melatonin and 5-lipoxygenase: An unexpected relationship. J Pineal Res 1995;18:171-178.
55. Conti A, Maestroni GJM: The clinical neu-roimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995;19:103-110.
56. Neri B, Fiorclli C, Moroni F. Nicita G. Paolctti MC. Ponchielti R, Raugei A, Santoni G. Trip-pitelli A. Grechi G: Modulation of human lym-phoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer 1994;73:3015-3019.
57. Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G. Alderi G. Lavorato F: Immune effects of prcopcrativc immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dosc intcrleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents 1995;9: 31-33.
58. Withyachumnamkul B, Nonaka KO, Santana C, Attia AM, Reiter RJ: Interferon-gamma modulates melatonin production in rat pineal gland in organ culture. J Interferon Res 1990; 10:403-411.
59. Zylinska K. Komorowski J, Robak T, Mucha S: Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatonin secretion in rats in vivo and in vitro studies. J Neuroimmunol 1995;56: 187-190.
60. Stepien H, Valcavi R, Zini M, Maestroni GJM, Conti A. Portioli I: Melatonin stimulates growth hormone secretion through pathways other than growth hormone-releasing hormone. Clin Endocrinol 1993;39:193-199.
61. Moccheggiani E, Bulian D, Santarelli L, Tibal-di A, Muzzioli M. Lesnikov V, Pierpaoli W, Fabris N: The zinc pool is involved in the immune-reconstituting effect of melatonin in pinealectomized mice. J Pharmacol Exp Thcr 1996;277:1200-1208.
62. Del Prete G, Maggi E, Romagnani S: Human Thl and Th2 cells: Functional properties, mechanisms of regulation and role in disease. Lab Invest 1994;70:299-307.
63. Hiddinga HJ, Isaak DD, Lewis RV: Enkephalin-containing peptides processed from proenkephalin significantly enhance the antibody-forming cell responses to antigens. J Immunol 1994; 152:3748-3755.
64. Sei S, Akiyoshi H, Bernard J, Venzon DJ, Fox CH, Schwartzentruber DJ, Anderson BD. Kopp JB, Mueller BU, Pizzo PA: Dynamics of virus versus host interaction in children with human immunodeficiency virus type 1 infection. J Infect Dis 1996; 173:1485-1490.
65. Kintcr AL, Bende SM, Hardy EC, Jackson R, Fauci A: Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92:10985-10989.
66. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA: Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion on innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-3294.